News & Updates

The orally administered, small molecule, gut-targeted stabiliser of hypoxia-inducible factor-1α (HIF-1α) GB004 appears to improve disease activity in patients with ulcerative colitis, with the drug being well-tolerated, according to the results of a phase Ib trial.

In patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), higher body temperature and heart rate, along with low white cell counts, are strong predictors of testing positive for influenza, according to a recent Singapore study.

For individuals with class I obesity, a very low-calorie ketogenic diet (VLCKD) with omega-3 supplementation results in fat mass reduction while preserving fat-free mass (FFM), as shown in a study. Furthermore, there are improvements seen in satiety hormones, such as higher ghrelin and lower leptin, and in the metabolic profiles.

The risk stratification criteria used in the CHAARTED and LATITUDE trials can accurately assess prognosis in patients with castration-resistant prostate cancer (CRPC), but are insufficient to differentiate between the therapeutic outcomes of androgen receptor pathway inhibitors (ARPI) and docetaxel, a new study has found.

The novel highly selective mineralocorticoid receptor blocker esaxerenone holds promise in the treatment of nocturnal hypertension, yielding substantial reductions in night-time blood pressure (BP), especially in Japanese patients with a riser pattern, as well as in N-terminal pro B-type natriuretic peptide (NT-proBNP) levels, according to a post hoc analysis of a phase III study.

A peak systolic blood pressure (SBP) at clinical exercise testing that is slightly lower than the predicted value appears predictive of future cardiovascular disease (CVD) and mortality, suggests a study. Higher peak SBP, however, is not associated with such risks.